Current and historical daily PE Ratio for CytoMed Therapeutics Ltd (
) from 2023 to Jun 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. CytoMed Therapeutics stock (GDTC) PE ratio as of Jun 20 2024 is 0.
More Details
CytoMed Therapeutics Ltd (GDTC) PE Ratio (TTM) Chart
CytoMed Therapeutics Ltd (GDTC) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 298
- 1
- 2
- 3
- 4
CytoMed Therapeutics PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-20 | At Loss | 2024-04-16 | At Loss |
2024-06-18 | At Loss | 2024-04-15 | At Loss |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-04-01 | At Loss |
2024-06-03 | At Loss | 2024-03-28 | At Loss |
2024-05-31 | At Loss | 2024-03-27 | At Loss |
2024-05-30 | At Loss | 2024-03-26 | At Loss |
2024-05-29 | At Loss | 2024-03-25 | At Loss |
2024-05-28 | At Loss | 2024-03-22 | At Loss |
2024-05-24 | At Loss | 2024-03-21 | At Loss |
2024-05-23 | At Loss | 2024-03-20 | At Loss |
2024-05-22 | At Loss | 2024-03-19 | At Loss |
2024-05-21 | At Loss | 2024-03-18 | At Loss |
2024-05-20 | At Loss | 2024-03-15 | At Loss |
2024-05-17 | At Loss | 2024-03-14 | At Loss |
2024-05-16 | At Loss | 2024-03-13 | At Loss |
2024-05-15 | At Loss | 2024-03-12 | At Loss |
2024-05-14 | At Loss | 2024-03-11 | At Loss |
2024-05-13 | At Loss | 2024-03-08 | At Loss |
2024-05-10 | At Loss | 2024-03-07 | At Loss |
2024-05-09 | At Loss | 2024-03-06 | At Loss |
2024-05-08 | At Loss | 2024-03-05 | At Loss |
2024-05-07 | At Loss | 2024-03-04 | At Loss |
2024-05-06 | At Loss | 2024-03-01 | At Loss |
2024-05-03 | At Loss | 2024-02-29 | At Loss |
2024-05-02 | At Loss | 2024-02-28 | At Loss |
2024-05-01 | At Loss | 2024-02-27 | At Loss |
2024-04-30 | At Loss | 2024-02-26 | At Loss |
2024-04-29 | At Loss | 2024-02-23 | At Loss |
2024-04-26 | At Loss | 2024-02-22 | At Loss |
2024-04-25 | At Loss | 2024-02-21 | At Loss |
2024-04-24 | At Loss | 2024-02-20 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
2024-04-17 | At Loss | 2024-02-12 | At Loss |
CytoMed Therapeutics Ltd (GDTC) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
CytoMed Therapeutics Ltd
ISIN : SGXZ17669631
Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.